BACKGROUND: Clinical stage T2c (cT2c) is an indeterminate factor in @entity263 ( @entity263 ) risk stratification. According to the D'Amico grouping and American Urological Association guidelines, cT2c is a high risk, whereas the National @entity5 Network and the European Urological Association classify cT2c as an intermediate risk. This study assessed whether cT2c @entity5 without other high-risk factors (clinical stage T2c, not otherwise specified [cT2c-NOS]) behaved as an intermediate or high risk through an analysis of biochemical recurrence (BCR) after radical prostatectomy. METHODS: Two thousand seven hundred fifty-nine @entity1 from the @entity5 ( @entity5 ) Database and 12,900 @entity1 from Johns Hopkins Hospital (JHH) from 1988-2011 and 1982-2012, respectively, were analyzed. @entity1 were grouped into low-risk ( @entity1486 , Gleason sum  <= 6, and @entity7487 -T2a), intermediate-risk (PSA = 10-20 ng/mL, Gleason sum = 7, or cT2b), and high-risk @entity263 categories (PSA > 20 ng/mL, Gleason sum = 8-10, or @entity16178 ). @entity1 with cT2c @entity5 who were not otherwise at high risk (ie, PSA< 20 ng/mL and Gleason sum < 8) were placed into a separate category termed cT2c-NOS. Associations between cT2c-NOS and intermediate- and high-risk @entity1 and BCR were tested with the log-rank test and Cox proportional analysis models. RESULTS: Ninety-nine @entity1 (4%) from @entity5 and 202 @entity1 (2%) from JHH had @entity5 classified as cT2c-NOS. The cT2c-NOS @entity1 had a BCR risk similar to that of the intermediate-risk @entity1 ( @entity5 , P = .27; JHH, P = .23) but a significantly lower BCR risk in comparison with the high-risk @entity1 ( @entity5 , P < .001; JHH, P < .001). When they were specifically compared with intermediate- and high-risk @entity1 , after adjustments for year and center, cT2c-NOS @entity1 had outcomes comparable to those of intermediate-risk @entity1 ( @entity5 , P = .53; JHH, P = .54) but significantly better than those of high-risk @entity1 ( @entity5 , P = .003; JHH, P < .001). CONCLUSIONS: @entity1 with cT2c disease without other high-risk features had outcomes similar to the outcomes of @entity1 with intermediate-risk @entity263 and significantly better than the outcomes of @entity1 with high-risk @entity263 . These findings suggest that @entity1 with cT2c disease should be considered to be at intermediate risk. @entity5 2014.    2014 American @entity5 Society.

Is clinical stage T2c XXXX an intermediate- or high-risk disease?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Men', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'PC'] @entity7487 :: ('1489', 'Gene') :: ['cT1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['SEARCH', 'Shared Equal Access Regional Cancer Hospital', 'Cancer', 'Comprehensive Cancer', 'tumors'] @entity16178 :: ('285782', 'Gene') :: ['cT3'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen [PSA] < 10 ng/mL']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
